Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 2, 2020

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2029

Conditions
GlioblastomaMalignant GliomaRecurrent GlioblastomaRecurrent Malignant GliomaRecurrent Grade III GliomaGrade III Glioma
Interventions
BIOLOGICAL

Nivolumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies, given in person or online

OTHER

Questionnaire Administration

Ancillary studies, given in person or online

Trial Locations (20)

1291

RECRUITING

Sydney Children's Hospital, Sydney

2152

RECRUITING

The Children's Hospital at Westmead, Westmead

3052

RECRUITING

Royal Children's Hospital, Parkville

4101

RECRUITING

Queensland Children's Hospital, South Brisbane

5006

RECRUITING

Women's and Children's Hospital, North Adelaide

6009

RECRUITING

Perth Children's' Hospital, Perth

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

20310

RECRUITING

Children's National Hospital, Washington D.C.

21287

RECRUITING

Johns Hopkins University, Baltimore

27705

RECRUITING

Duke Children's Hospital & Health Center, Durham

32611

RECRUITING

University of Florida, Gainesville

35233

RECRUITING

University of Alabama at Birmingham, Children's of Alabama, Birmingham

46202

RECRUITING

Riley Children's Hospital, Indianapolis

63110

RECRUITING

Washington University St. Louis, St Louis

84113

RECRUITING

University of Utah, Salt Lake City

90027

RECRUITING

Children's Hospital of Los Angeles, Los Angeles

92123

RECRUITING

Rady Children's Hospital, San Diego

94115

RECRUITING

University of California, San Francisco, San Francisco

02215

RECRUITING

Dana Farber Cancer Institute, Boston

07601

RECRUITING

Hackensack Meridian Children's Health at Joseph M. Sanzari Children's Hospital, Hackensack

All Listed Sponsors
collaborator

Pediatric Neuro-Oncology Consortium

OTHER

lead

Sabine Mueller, MD, PhD

OTHER

NCT04323046 - Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | Biotech Hunter | Biotech Hunter